Featured Image
Why is it important?
The results of recent cancer clinical trials should be interpreted with caution.
Read the Original
This page is a summary of: Did the Randomized Phase III KEYNOTE-181 Study of Pembrolizumab for Esophageal Cancer Yield Negative or Positive Results?, Journal of Clinical Oncology, April 2021, American Society of Clinical Oncology (ASCO),
DOI: 10.1200/jco.20.03262.
You can read the full text:
Contributors
The following have contributed to this page
